Bob Dagher joined Brainstorm in July 2023 and currently serves as Executive Vice President and Chief Development Officer. Dr. Dagher has over twenty years of experience in the pharmaceutical industry and is a past board-certified physician from the American Board of neurology and psychiatry. He has an extensive therapeutic background concentrated in the neuroscience space with a focus on neurodegenerative, neuroinflammatory, and movement disorders.

Following his early experience treating patients in academic and private settings, Dr. Dagher started his career in the pharmaceutical industry at GlaxoSmithKline, followed by joining other organizations such as Genzyme, Sanofi Aventis where he worked on developing new medications for neurological, psychiatric, and rare diseases. Prior to joining Brainstorm, Dr. Dagher served as the Chief Medical Officer (CMO) at Enveric Biosciences, and prior to that he was the CMO of WCG Medavante-Prophase and Cadent Therapeutics. Furthermore, Dr. Dagher has supported and driven successful drug development programs from preclinical stages, into phases 1, 2 and 3, and through Phase 4 post-marketing label expansion. He is an innovator and analytical person who tirelessly works on creating scientific solutions to match the industry challenges of bringing novel therapeutics across different platforms and indications.

Bob obtained his medical degree (MD) through a joint program between St. Joseph and Bordeaux universities and has completed residency training at Boston University School of Medicine. He brings expertise through his work as a physician scientist and drug developer in the pharmaceutical industry, along with a strong passion for developing innovative therapeutics for neurological and rare diseases.